

Summary of Consolidated Financial Results [IFRS]
for the First Three Months of the Fiscal Year Ending March 31, 2026

August 6, 2025

Listed company name : Sysmex Corporation
Code : 6869
Listed stock exchanges : Tokyo Stock Exchange
URL : www.sysmex.co.jp/en
Company representative : Kaoru Asano, President
Contact : Takuro Minami, Executive Vice President of
Corporate Business Administration
Phone : 078(265)-0500
Scheduled date for dividend payment : —
Preparation of supplementary material for
quarterly earnings : Yes
Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the First Three Months of the Fiscal Year Ending March 31, 2026

(1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Three months ended Jun. 30, 2025	105,731	(5.6)%	10,628	(36.5)%	7,873	(53.6)%	4,476	(59.2)%
Three months ended Jun. 30, 2024	111,946	17.4%	16,743	26.1%	16,979	29.0%	10,984	28.3%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Three months ended Jun. 30, 2025	4,553	(58.7)%	8,059	(67.3)%	7.30	7.30
Three months ended Jun. 30, 2024	11,031	28.0%	24,618	8.0%	17.69	17.69

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Jun. 30, 2025	639,928	462,022	461,340	72.1
As of Mar. 31, 2025	665,268	464,534	463,776	69.7

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2025	—	15.00	—	17.00	32.00
Year ending Mar. 31, 2026	—				
Year ending Mar. 31, 2026 (Forecast)		19.00	—	19.00	38.00

Notes:

1. Revision of dividends forecast for this period: No
2. Details of the dividends for the fiscal year ending March 31, 2026
Second quarter Ordinary dividend: ¥18.00
 Commemorative dividend: ¥1.00 (30th anniversary of listing)
Year-end Ordinary dividend: ¥18.00
 Commemorative dividend: ¥1.00 (30th anniversary of listing)

3. Financial Forecast for the Year Ending March 31, 2026

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Six months ending Sep. 30, 2025	240,000	(1.0)%	36,000	(19.1)%	31,500	(17.7)%	20,000	(23.1)%	32.07
Year ending Mar. 31, 2026	535,000	5.2%	91,500	4.5%	85,500	7.9%	57,000	6.2%	91.40

Note: Revision of financial forecast for this period: Yes

4. Other Information

- (1) Significant changes in scope of consolidation:
No
- (2) Changes in accounting policies and accounting estimates
 - 1) Changes in accounting policies required by IFRS: No
 - 2) Other changes in accounting policies: No
 - 3) Changes in accounting estimates: No
- (3) Number of outstanding stock (common stock)
 - 1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,480,076 shares as of Jun. 30, 2025; 629,473,176 shares as of Mar. 31, 2025
 - 2) Number of treasury stock at the end of each fiscal period:
5,869,884 shares as of Jun. 30, 2025; 5,873,371 shares as of Mar. 31, 2025
 - 3) Average number of outstanding stock for each period (cumulative):
623,604,502 shares for the three months ended Jun. 30, 2025
623,498,103 shares for the three months ended Jun. 30, 2024

Note: The Company has introduced Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

* Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: Yes

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Qualitative information on quarterly financial results” on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Wednesday, August 6, 2025.

Content of Supplementary Materials

1. Qualitative information on quarterly financial results	2
1) Operating performance analysis	2
2) Financial conditions analysis	3
3) Consolidated financial forecast	4
4) Operating risks	4
5) Priority business and financial issues to be addressed	4
6) Important contracts, etc.	4
2. Condensed quarterly consolidated financial statements and notes	5
1) Condensed quarterly consolidated statement of financial position	5
2) Condensed quarterly consolidated statement of income	7
3) Condensed quarterly consolidated statement of comprehensive income	8
4) Condensed quarterly consolidated statement of changes in equity	9
5) Condensed quarterly consolidated statement of cash flows	10
6) Notes to the condensed quarterly consolidated financial statements	11
1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements	11
2. Notes related to the going concern assumption	11
3. Segment information	11

1. Qualitative information on quarterly financial results

Future-related information contained in the text below is based on the judgement as of the end of the fiscal period under review.

1) Operating performance analysis

The Group's consolidated financial results for the first quarter of the fiscal year ending March 31, 2026 are as follows.

Net sales by destination

	Three months ended June 30, 2024		Three months ended June 30, 2025		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	13,717	12.3	11,011	10.4	80.3
Americas	31,638	28.3	30,205	28.6	95.5
EMEA (Europe, the Middle East, and Africa)	34,726	31.0	35,151	33.2	101.2
China	19,522	17.4	17,272	16.4	88.5
AP (Asia Pacific)	12,340	11.0	12,090	11.4	98.0
Overseas subtotal	98,228	87.7	94,720	89.6	96.4
Total	111,946	100.0	105,731	100.0	94.4

In Japan, reagent sales decreased in the immunochemistry, hemostasis, and hematology fields. In the medical robotics business, sales of consumables rose, but instrument sales declined. As a result, sales in Japan fell 19.7% year on year, to ¥11,011 million. The ratio of sales in Japan decreased 1.9 percentage points, to 10.4%.

Overseas, sales of hematology instruments, reagents, and maintenance services declined. This factor, coupled with appreciation of the yen in foreign exchange markets, caused overseas sales to fall 3.6%, to ¥94,720 million. The overseas sales ratio rose 1.9 percentage points, to 89.6%.

Selling, general and administrative (SG&A) expenses totaled ¥38,296 million, up 6.3% year on year, due primarily to an increase in personnel and other costs associated with business expansion, as well as higher amortization expenses related to investments in digital infrastructure. R&D expenses came to ¥6,407 million, down 12.9%.

As a result, on a consolidated basis for the first quarter of the fiscal year ending March 31, 2026, net sales amounted to ¥105,731 million (down 5.6% year on year), operating profit was ¥10,628 million (down 36.5%), profit before tax was ¥7,873 million (down 53.6%), and profit attributable to owners of the parent totaled ¥4,553 million (down 58.7%).

Performance by segment

(1) Headquarters

Sales of reagents declined in the immunochemistry, hematology, and hemostasis fields. In the medical robotics business, while sales of consumables increased, sales of instruments declined. As a result, sales totaled ¥17,001 million (down 14.0% year on year).

On the profit front, in addition to the decline in sales, a worsening cost of sales ratio and an increase in SG&A expenses led to a segment profit (operating profit) of ¥2,227 million (down 79.3%).

(2) Americas RHQ

In North, Central and South America, sales of instruments, reagents, and maintenance services in the urinalysis field increased. However, in North America, sales of instruments, reagents, and maintenance services in the hematology field decreased, while in Central and

South America, sales of instruments and reagents in the hematology field also declined. As a result, sales in the Americas were ¥28,579 million (down 4.0% year on year).

Segment profit (operating profit) decreased to ¥801 million (down 55.2%), mainly due to the decline in sales and a worsening cost of sales ratio.

(3) EMEA RHQ

Sales of reagents in the life science field increased, as did sales of instruments and reagents in the urinalysis field. In the hematology field sales of instruments increased, while sales of reagents decreased. As a result, regional sales totaled ¥33,982 million (up 0.4% year on year).

Although gross profit was flat year on year, segment profit (operating profit) decreased to ¥2,263 million (down 34.9% year on year), mainly due to an increase in selling, general and administrative expenses resulting from business expansion.

(4) China RHQ

Sales of instruments, reagents, and maintenance services in the hemostasis field increased. Conversely, sales of instruments, reagents, and maintenance services decline in the hematology field declined. As a result, sales for the region were ¥17,235 million (down 11.5% year on year).

Despite the lower sales, segment profit (operating profit) rose to ¥1,672 million (up 199.9%), reflecting improvements in the cost of sales ratio due to increased production at the Jinan Factory and a reduction in SG&A expenses.

(5) AP RHQ

In the Asia Pacific region, sales of hemostasis reagents increased, while sales of hematology instruments and maintenance services declined. As a result, sales amounted to ¥8,931 million (down 1.7% year on year).

Although SG&A expenses decreased, a decline in sales and a worsening cost of sales ratio led to segment profit (operating profit) of ¥1,535 million (down 8.0%).

2) Financial conditions analysis

(1) Financial conditions

As of June 30, 2025, total assets amounted to ¥639,928 million, a decrease of ¥25,340 million compared with March 31, 2025. This fall was primarily due to declines of ¥19,675 million in trade and other receivables under current assets and ¥15,094 million in cash and cash equivalents. These declines more than offset increases of ¥6,118 million in inventories and ¥1,976 million in intangible assets.

Total liabilities decreased by ¥22,828 million from March 31, 2025, to ¥177,906 million. The main factors included reductions of ¥9,086 million in income taxes payable, ¥8,100 million in accrued bonuses, ¥3,937 million in trade and other payables, and ¥1,191 million in contract liabilities.

Total equity decreased by ¥2,512 million from March 31, 2025, to ¥462,022 million. While other components of equity increased by ¥3,624 million, this was outweighed by a ¥6,089 million decrease in retained earnings. As a result, the equity attributable to owners of the parent to total assets rose 2.4 percentage points, from 69.7% as of March 31, 2025, to 72.1%.

(2) Cash flows

As of June 30, 2025, cash and cash equivalents amounted to ¥74,476 million, down ¥15,094 million from March 31, 2025.

Cash flows from various activities during the first quarter are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥9,492 million (down ¥8,474 million from the first three months of the previous fiscal year). As principal factors, depreciation and amortization provided ¥10,762 million (up ¥975 million), decrease in trade receivable provided ¥19,122 million (up ¥2,102 million), decrease in accrued bonuses used ¥8,014 million (up ¥2,039 million), and income taxes paid amounted to ¥11,643 million (up ¥1,321 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥12,102 million (up ¥969 million). Among major factors, purchases of property, plant and equipment used ¥5,691 million (up ¥947 million), and purchases of intangible assets used ¥6,427 million (up ¥943 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥13,301 million (up ¥4,291 million). This was mainly due to dividends paid of ¥10,601 million (up ¥1,872 million), and repayments of lease liabilities of ¥2,547 million (up ¥94 million).

3) Consolidated financial forecast

For the Company's consolidated financial forecast for the Six Months Ended September 30, 2025, please refer to the Announcement Regarding Revision of Financial Forecast for the Six Months Ended September 30, 2025, announced today (August 6, 2025).

4) Operating risks

In the first quarter under review, no new operating risk emerged, and there were no material changes to the operating risks outlined in our financial report for the previous fiscal year.

5) Priority business and financial issues to be addressed

There are no significant changes to the descriptions of "Priority business and financial issues to be addressed" in "Part I: Corporate Information, Section 2: Business Overview, 1. Management Policy, Management Environment and Issues to be Addressed" in the financial report for the previous fiscal year.

6) Important contracts, etc.

No conclusions of important contracts or decisions regarding them were made during the first quarter under review.

2. Condensed quarterly consolidated financial statements and notes

1) Condensed quarterly consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Assets		
Current assets		
Cash and cash equivalents	89,570	74,476
Trade and other receivables	163,007	143,332
Inventories	81,811	87,929
Other short-term financial assets	654	117
Income taxes receivable	1,246	1,786
Other current assets	28,531	29,495
Total current assets	364,821	337,137
Non-current assets		
Property, plant and equipment	130,211	130,576
Goodwill	14,205	14,568
Intangible assets	92,146	94,122
Investments accounted for using the equity method	339	289
Trade and other receivables	26,978	27,678
Other long-term financial assets	12,034	12,411
Asset for retirement benefits	0	23
Other non-current assets	6,880	6,901
Deferred tax assets	17,651	16,219
Total non-current assets	300,447	302,791
Total assets	665,268	639,928

(Unit: Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	31,865	27,927
Lease liabilities	9,250	9,496
Other current financial liabilities	1,403	1,249
Income taxes payable	12,784	3,697
Provisions	1,164	1,115
Contract liabilities	18,098	16,907
Accrued expenses	22,355	21,455
Accrued bonuses	14,709	6,609
Other current liabilities	11,194	11,518
Total current liabilities	122,826	99,978
Non-current liabilities		
Long-term loans payable	32,359	32,181
Lease liabilities	23,126	22,801
Other non-current financial liabilities	56	51
Liability for retirement benefits	2,127	2,254
Provisions	1,054	1,091
Other non-current liabilities	11,608	11,716
Deferred tax liabilities	7,575	7,831
Total non-current liabilities	77,908	77,927
Total liabilities	200,734	177,906
Equity		
Equity attributable to owners of the parent		
Capital stock	14,887	14,898
Capital surplus	20,960	20,970
Retained earnings	402,820	396,731
Treasury stock	(12,318)	(12,309)
Other components of equity	37,425	41,050
Total equity attributable to owners of the parent	463,776	461,340
Non-controlling interests	758	681
Total equity	464,534	462,022
Total liabilities and equity	665,268	639,928

2) Condensed quarterly consolidated statement of income

(Unit: Millions of yen)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Net sales	111,946	105,731
Cost of sales	51,906	51,267
Gross profit	60,039	54,463
Selling, general and administrative expenses	36,016	38,296
Research and development expenses	7,356	6,407
Other operating income	234	1,084
Other operating expenses	157	215
Operating profit	16,743	10,628
Financial income	213	198
Financial expenses	590	909
Share of profit (loss) of associates accounted for using the equity method	(770)	(534)
Foreign exchange gain (loss)	1,384	(1,508)
Profit before tax	16,979	7,873
Income taxes expenses	5,995	3,397
Profit	10,984	4,476
Profit attributable to		
Owners of the parent	11,031	4,553
Non-controlling interests	(47)	(76)
Profit	10,984	4,476
(Unit: Yen)		
Earnings per share		
Basic	17.69	7.30
Diluted	17.69	7.30

3) Condensed quarterly consolidated statement of comprehensive income

(Unit: Millions of yen)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Profit	10,984	4,476
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(736)	154
Total	(736)	154
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	14,353	3,422
Share of other comprehensive income of investments accounted for using the equity method	17	5
Total	14,370	3,428
Total other comprehensive income	13,634	3,582
Comprehensive income	24,618	8,059
Comprehensive income attributable to		
Owners of the parent	24,665	8,135
Non-controlling interests	(47)	(76)
Comprehensive income	24,618	8,059

4) Condensed quarterly consolidated statement of changes in equity

Three months ended June 30, 2024

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2024	14,729	20,830	365,917	(12,315)	42,814	432,045	851	432,897
Profit	—	—	11,031	—	—	11,031	(47)	10,984
Other comprehensive income	—	—	—	—	13,634	13,634	—	13,634
Comprehensive income	—	—	11,031	—	13,634	24,665	(47)	24,618
Exercise of warrants	—	—	—	—	—	—	—	—
Share-based payment transactions	—	—	—	—	—	—	—	—
Cash dividends	—	—	(8,728)	—	—	(8,728)	—	(8,728)
Purchase of treasury stock	—	—	—	(2)	—	(2)	—	(2)
Disposal of treasury stock	—	0	—	0	—	0	—	0
Transfer to retained earnings	—	—	—	—	—	—	—	—
Total transactions with the owners	—	0	(8,728)	(2)	—	(8,731)	—	(8,731)
As of June 30, 2024	14,729	20,831	368,288	(12,318)	56,449	447,979	804	448,784

Three months ended June 30, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
Profit	—	—	4,553	—	—	4,553	(76)	4,476
Other comprehensive income	—	—	—	—	3,582	3,582	—	3,582
Comprehensive income	—	—	4,553	—	3,582	8,135	(76)	8,059
Exercise of warrants	10	6	—	—	—	16	—	16
Share-based payment transactions	—	13	—	—	—	13	—	13
Cash dividends	—	—	(10,601)	—	—	(10,601)	—	(10,601)
Purchase of treasury stock	—	—	—	—	—	—	—	—
Disposal of treasury stock	—	(9)	—	9	—	—	—	—
Transfer to retained earnings	—	—	(41)	—	41	—	—	—
Total transactions with the owners	10	9	(10,642)	9	41	(10,571)	—	(10,571)
As of June 30, 2025	14,898	20,970	396,731	(12,309)	41,050	461,340	681	462,022

5) Condensed quarterly consolidated statement of cash flows

(Unit: Millions of yen)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Cash flows from operating activities		
Profit before tax	16,979	7,873
Depreciation and amortization	9,786	10,762
Share of loss (profit) of associates accounted for using the equity method	770	534
Loss on retirement of non-current assets	31	57
Decrease (increase) in trade receivable	17,019	19,122
Decrease (increase) in advance payments	(94)	(794)
Decrease (increase) in inventories	(6,030)	(4,757)
Increase (decrease) in trade payable	(3,637)	(2,016)
Increase (decrease) in accounts payable—other	(1,767)	(608)
Increase (decrease) in contract liabilities	(524)	(937)
Increase (decrease) in accrued expenses	1,063	(827)
Decrease/increase in consumption taxes receivable/payable	1,551	1,898
Increase (decrease) in accrued bonuses	(5,975)	(8,014)
Other—net	(646)	(784)
Subtotal	28,527	21,507
Interest and dividend received	166	168
Interest paid	(405)	(540)
Income taxes paid	(10,321)	(11,643)
Net cash provided by (used in) operating activities	17,966	9,492
Cash flows from investing activities		
Purchases of property, plant and equipment	(4,743)	(5,691)
Purchases of intangible assets	(5,484)	(6,427)
Payments resulting in an increase in long-term prepaid expenses	(258)	(165)
Purchases of investments in equity instruments	(801)	(49)
Payments into time deposits	(620)	(19)
Proceeds from withdrawal of time deposits	741	434
Other—net	34	(182)
Net cash provided by (used in) investing activities	(11,132)	(12,102)
Cash flows from financing activities		
Proceeds from long-term loans payable	2,300	—
Repayments of long-term loans payable	(125)	(178)
Exercise of warrants	—	16
Dividends paid	(8,728)	(10,601)
Repayments of lease liabilities	(2,453)	(2,547)
Other—net	(2)	9
Net cash provided by (used in) financing activities	(9,010)	(13,301)
Effects of exchange rate changes on cash and cash equivalents	3,426	817
Net increase (decrease) in cash and cash equivalents	1,249	(15,094)
Cash and cash equivalents at the beginning of the term	75,507	89,570
Cash and cash equivalents at the end of the term	76,757	74,476

6) Notes to the condensed quarterly consolidated financial statements

1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements

The condensed quarterly consolidated financial statements have been prepared in accordance with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordance with Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, some disclosures in International Accounting Standard No. 34 “Interim Financial Reporting” are omitted.)

2. Notes related to the going concern assumption

Not applicable

3. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

The five managing company-specific segments are “Headquarters,” “Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 12 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 12 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 26 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai Ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Three months ended June 30, 2024

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	19,759	29,785	33,837	19,477	9,086	111,946	—	111,946
Intersegment sales	33,036	5	151	176	10	33,380	(33,380)	—
Total	52,796	29,790	33,988	19,654	9,097	145,326	(33,380)	111,946
Segment profit (loss)	10,748	1,789	3,475	557	1,668	18,238	(1,495)	16,743
Financial income	—	—	—	—	—	—	—	213
Financial expenses	—	—	—	—	—	—	—	590
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(770)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	1,384
Profit before tax	—	—	—	—	—	—	—	16,979
Income taxes expenses	—	—	—	—	—	—	—	5,995
Profit	—	—	—	—	—	—	—	10,984

Notes:

1. Segment profit (loss) adjustments of negative ¥1,495 million include negative ¥1,435 million for the unrealized gains on inventories and negative ¥59 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

Three months ended June 30, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	17,001	28,579	33,982	17,235	8,931	105,731	—	105,731
Intersegment sales	26,712	8	109	48	10	26,889	(26,889)	—
Total	43,713	28,588	34,092	17,283	8,942	132,620	(26,889)	105,731
Segment profit (loss)	2,227	801	2,263	1,672	1,535	8,499	2,129	10,628
Financial income	—	—	—	—	—	—	—	198
Financial expenses	—	—	—	—	—	—	—	909
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(534)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(1,508)
Profit before tax	—	—	—	—	—	—	—	7,873
Income taxes expenses	—	—	—	—	—	—	—	3,397
Profit	—	—	—	—	—	—	—	4,476

Notes:

1. Segment profit (loss) adjustments of ¥2,129 million include ¥2,222 million for the unrealized gains on inventories and negative ¥93 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.